Onassis Holdings Corp (OTC: ONSS), a biotech-focused holding company specializing in longevity and rejuvenation technologies, has announced the launch of a Regulation A+ financing round through an agreement with Dalmore Group. This initiative allows the company to raise up to $75 million annually from the public, leveraging Dalmore's extensive experience and market relationships.
Dalmore Group, which has onboarded more than 270 Reg A+ issuers since 2021, brings over 16 years of experience to the partnership. The firm offers marketing and PR support, marketplace syndication, and secondary trading solutions for issuers, which could significantly enhance Onassis Holdings' ability to attract investors and raise capital efficiently.
According to the press release, Onassis Holdings Corp is a biotech holdings company specializing in longevity and rejuvenation technologies through epigenetic reprogramming. The company's subsidiary, Ananda Labs, focuses on creating groundbreaking therapies based on patented proteins that rejuvenate elderly cells while maintaining their distinct properties. This financing round is expected to accelerate the development and commercialization of these therapies.
The Regulation A+ offering, often referred to as a "mini-IPO," allows companies to raise capital from the general public, including non-accredited investors, with less stringent regulatory requirements than a traditional IPO. This approach can provide Onassis with a broader investor base and greater flexibility in fundraising.
Investors interested in learning more about the company can visit the Onassis Holdings website at https://www.onassis-holdings.com/. The full press release is available at https://ibn.fm/s9HOQ.
This development is significant for the biotech sector as it highlights the growing trend of using Regulation A+ offerings to fund innovative therapeutic research. For Onassis Holdings, the ability to raise substantial capital from the public could provide the resources needed to advance its epigenetic reprogramming technologies, which aim to reverse cellular aging and improve longevity.
Industry observers will be watching closely to see how the financing proceeds and whether Onassis can deliver on its promise of groundbreaking rejuvenation therapies. The company's focus on patented proteins that rejuvenate cells without altering their identity sets it apart in the competitive longevity space.
